The story
Natco Pharma was founded in 1981 by V C Nannapaneni. In 1983, operations commenced at manufacturing facility at Kothur. In 1986 NATCO established a manufacturing facility at Nagarjuna Sagar, Andhra Pradesh. In 1993, the company's chemical division started at Mekaguda near Hyderabad.
In 2008, Natco Pharma filed its first paragraph IV filing in the US with the USFDA, In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar. In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.
In 2016, Natco Pharma launched the first Tamiflu capsule in the US market. In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide in the United States. In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.
In 2025, Natco Pharma completed the acquisition of a 35.75% stake in Adcock Ingram, a South African pharmaceutical company, for approximately US$226 million. The acquisition resulted in the delisting of Adcock Ingram from the Johannesburg Stock Exchange.
Hyderabad-based Natco Pharma Limited on Tuesday completed the acquisition of an additional 13.25 per cent equity stake in South African pharmaceutical company Adcock Ingram Holdings Proprietary Limited, bringing its total shareholding to 49 per cent.[1]
Export Formulations
Has over three decades of expertise in targeting niche and complex molecules. Business spans across key regulated markets including US, Canada, Brazil, Indonesia, Singapore, LATAM, MENA countries.
From Wikipedia’s article on Natco Pharma, shared under CC BY-SA 4.0.5